Use Code ONLINE20 to Save 20% On Global Market Reports – Gain Access to Trusted Market Data, Growth Indicators, and Industry Analytics
What Is the Estimated Market Size and CAGR of the Nebivolol Tablets Market for the Period 2025–2029?
The nebivolol tablets market size has grown strongly in recent years. It will grow from $1.14 billion in 2024 to $1.22 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to increasing global prevalence of hypertension, rising awareness of cardiovascular health, a growing aging population susceptible to heart conditions, expansion of healthcare infrastructure in developing regions, and rising diagnosis rates of heart failure.
The nebivolol tablets market size is expected to see strong growth in the next few years. It will grow to $1.57 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to rising healthcare expenditure per capita, growing adoption of sedentary lifestyles leading to cardiovascular risks, expanding urbanization associated with dietary and stress-related factors, increasing prevalence of comorbid conditions such as diabetes, and rising investment in public cardiovascular health campaigns. Major trends in the forecast period include ongoing innovations in drug delivery technologies, development of extended-release formulations, growing integration of digital health platforms for medication adherence, advances in manufacturing efficiency and quality control, and increasing focus on sustainable pharmaceutical packaging.
Get your free report sample today:
Which Core Drivers Are Expected to Drive Demand Within the Nebivolol Tablets Market?
The increasing prevalence of cardiovascular diseases is expected to propel the growth of the nebivolol tablets market going forward. Cardiovascular diseases include various disorders that impact the heart and blood vessels, often involving restricted blood flow that may lead to severe conditions such as heart attacks or strokes. Cardiovascular diseases are rising due to inactive lifestyles, which reduce physical movement and raise the chances of developing issues such as obesity, high blood pressure, and weakened heart function. Nebivolol tablets aid in preventing cardiovascular diseases by lowering blood pressure through selective beta-1 receptor blocking and enhancing nitric oxide-related vasodilation, which boosts blood circulation and eases the heart’s workload. For instance, in December 2024, according to the Australian Institute of Health and Welfare, an Australia-based national agency, Australia recorded 331,400 cardiovascular disease-related emergency visits (1,300 per 100,000 people) in 2022-23. Of these, 5.2% needed resuscitation, 44% were emergencies, 37% were urgent, 12% were semi-urgent, and 1.4% were non-urgent. Therefore, the increasing prevalence of cardiovascular diseases is driving the growth of the nebivolol tablets market.
The growing demand for generic drugs is expected to propel the growth of the nebivolol tablets market going forward. Generic drugs are pharmaceutical products that contain the same active ingredients, strength, dosage form, and route of administration as their brand-name counterparts but are marketed under their chemical name after the original drug's patent has expired. The demand for generic drugs is driven by their affordability, as they provide the same medical benefits as branded drugs at much lower costs, increasing accessibility for more people. Nebivolol tablets contribute to generic drugs by providing an affordable and therapeutically equivalent alternative to brand-name treatments for high blood pressure and heart conditions. For instance, in September 2024, according to the Association for Accessible Medicines (AAM), a US-based trade association, savings from the use of biosimilars rose by over 30% to $12.4 billion in 2023, while total savings from generics and biosimilars grew by $37 billion, reaching $445 billion from $408 billion in 2022. Therefore, the growing demand for generic drugs is driving the growth of the nebivolol tablets market.
What Are the Primary Market Segments in the Nebivolol Tablets Market?
The nebivolol tablets market covered in this report is segmented –
1) By Dosage Form: Immediate Release Tablets, Extended Release Tablets
2) By Strength: 2.5 Mg Tablets, 5 Mg Tablets, 10 Mg Tablets
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
4) By Application: Hypertension, Heart Failure, Other Applications
Subsegments:
1) By Immediate Release Tablets: Film-Coated Tablets, Uncoated Tablets, Dispersible Tablets, Orally Disintegrating Tablets, Sugar-Coated Tablets
2) By Extended Release Tablets: Modified-Release Matrix Tablets, Delayed-Release Tablets, Controlled-Release Tablets, Dual-Layer Tablets, Extended-Release Osmotic Tablets
Which Future-Ready Trends Are Expected to Influence the Nebivolol Tablets Market?
Major companies operating in the nebivolol tablets market are focusing on developing innovative products, such as generic antihypertensive tablets, to increase accessibility to essential hypertension treatments through cost-effective alternatives. A generic antihypertensive tablet is a non-branded pharmaceutical formulation that delivers the same active ingredient, dosage, safety, and efficacy as its branded counterpart to help manage elevated blood pressure. For instance, in May 2024, Apnar Pharma LP, a US-based pharmaceutical company, launched a generic version of Bystolic (Nebivolol Hydrochloride Tablets). The product was launched in all four available strengths, as 2.5 milligrams, 5 milligrams, 10 milligrams, and 20 milligrams, offering a full range of dosage options for prescribers and patients. This introduction marks the company’s strategic entry into the United States antihypertensive market and helps broaden access to an essential cardiovascular treatment.
Who Are the Major Companies Operating in the Nebivolol Tablets Market?
Major companies operating in the nebivolol tablets market are AbbVie Inc., Abbott Laboratories Inc., Eli Lilly and Company, Viatris Inc., Sandoz International GmbH, Macleods Pharmaceuticals Ltd., Menarini Group, Aurobindo Pharma, Cipla Inc., Lupin Limited, Zydus Group, Ranbaxy Laboratories Ltd., Glenmark Pharmaceuticals, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Zhejiang Huahai Pharmaceutical Co. Ltd., Aristo Pharmaceuticals Pvt. Ltd., Fuan Pharmaceutical Group Co. Ltd., ANI Pharmaceuticals Inc., Camber Pharmaceuticals Inc., Octavius Pharma
Get the detailed nebivolol tablets market report today
Which Region Holds the Largest Share of the Nebivolol Tablets Market?
North America was the largest region in the nebivolol tablets market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nebivolol tablets market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment